Need professional-grade analysis? Visit stockanalysis.com
$6.89M
N/A
506
N/A
Adaptimmune Therapeutics plc (ADAPY) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $0.02, up 900.00% from the previous close.
Over the past year, ADAPY has traded between a low of $0.00 and a high of $0.35. The stock has lost 92.0% over this period. It is currently 94.2% below its 52-week high.
Adaptimmune Therapeutics plc has a market capitalization of $6.89M.
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has a strategic collaboration with Galápagos for a clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galápagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; a collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Side-by-side comparison against top Healthcare peers.